Drug intelligence / Profile preview

XITRA

Development stage: Preclinical
Lead developer: Xitra Therapeutics
Modality: Small Molecules
Administration: Subcutaneous

Overview

XITRA is a proprietary small-molecule agonist developed by Constant Therapeutics that targets the Mas and MrgD receptors. These receptors are integral components of the alternative Renin-Angiotensin System (aRAS) pathway, which serves to counter-regulate the classical RAS pathway. By activating Mas and MrgD, XITRA is designed to promote vasodilation and exert anti-inflammatory and anti-fibrotic effects, specifically for the treatment of endothelial diseases. The compound is currently in the preclinical stage of development.

Brand names: XITRA

Targets

MRGPRD (Mas-related G protein-coupled receptor D)

Beyond the preview

Go deeper on XITRA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XITRA.

Explore the full profile